Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Blood (2023) 142 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2023-178505

Published: 2023

Journal Articles

SIE/Sies/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? a Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)

Blood (2023) 142 (Supplement 1): 956.

https://doi.org/10.1182/blood-2023-180568

Published: 2023

Journal Articles

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Blood (2023) 142 (Supplement 1): 731.

https://doi.org/10.1182/blood-2023-189025

Published: 2023

Journal Articles

Different Epidemiology and Characteristics of Invasive Pulmonary Aspergillosis in Acute Lymphoid Leukemia in Comparison with AML: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda (REL)

Chiara Cattaneo, Massimo Bernardi, Nicola Fracchiolla, Federica Gigli, Claudia Basilico, Lorenzo Masina, Erika Borlenghi, Alessandro Bruno, Giselda Gela, Diego Bertoli, Giuseppe Rossi, Alessandra Tucci, Federico Lussana, Elisabetta Todisco

Blood (2023) 142 (Supplement 1): 5827.

https://doi.org/10.1182/blood-2023-181212

Published: 2023

Journal Articles

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 6119–6121.

https://doi.org/10.1182/blood-2022-157937

Published: 2022

Journal Articles

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2021) 138 (Supplement 1): 1284.

https://doi.org/10.1182/blood-2021-146666

Published: 2021

Journal Articles

A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2021) 138 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2021-146681

Published: 2021

Journal Articles

Italian Observational Study on Real-Life Use of Venetoclax in Acute Myeloid Leukemia (AVALON study): Results of Interim Analysis on Relapsed/Refractory Patients

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-143082

Published: 2020

Journal Articles

B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions

Safaa M. Ramadan, PhD MD, Alessandro Cignetti, MD PhD, Simona Sammassimo, MD, Enrico Derenzini, MD PhD, Giusy Ceparano, MD, Tommaso Radice, MD, Federica Gigli, MD, Stefano Fiori, MD, Valentina Tabanelli, MD, Martina Milani, Emanuela Omodeo Sale', Sara Gandini, PhD, Daniela Gottardi, MD, Giuseppe Saglio, MD, Stefano Pileri, MD, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 1631.

https://doi.org/10.1182/blood-2019-128794

Published: 2019

Journal Articles

Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features

Daniele Avenoso, MD, Margherita Squillario, Annalisa Barla, Alessandro Verri, Enrico Carminati, Clara Nurra, Elisabetta Todisco, MD PhD, Federica Gigli, MD, Giuliana Gregato, Claudia Poletti, Francesco Bertolini, MD PhD, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Mili Shah, FRCPath, Maurizio Miglino

Blood (2019) 134 (Supplement_1): 5414.

https://doi.org/10.1182/blood-2019-130153

Published: 2019

Journal Articles

A Cellular Therapy with Haploidentical Peripheral Hematopoietic STEM CELL Transplantation MAY be a Therapeutic Option in Patients with Relapsed Lymphoma with Chemorefractory Disease

Simona Sammassimo, Daniele Avenoso, Federica Gigli, Daniele Laszlo, MD, Francesco Bertolini, MD PhD, Giammarco Russo, Corrado Tarella, MD Prof, Rocco Pastano

Blood (2018) 132 (Supplement 1): 2189.

https://doi.org/10.1182/blood-2018-99-119752

Published: 2018

Journal Articles

Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study

Enrico Derenzini, MD PhD, Angela Gueli, MD, Safaa Ramadan, PhD MD, Anna Vanazzi, MD, Simona Sammassimo, MD, Federica Gigli, MD, Niccolo' Frungillo, MD, Riccardo Bruna, MD, Alberto Agazzi, MD, Alberto De Crescenzo, MD, Rocco Pastano, MD, Laura L Travaini, MD, Chiara Grana, MD, Laszlo Daniele, MD, William Arcese, Corrado Tarella, MD

Blood (2016) 128 (22): 3003.

https://doi.org/10.1182/blood.V128.22.3003.3003

Published: 2016

Journal Articles

Unmanipulated, G-CSF Mobilized Peripheral Blood Stem Cells As Graft Source for Non-Myeloablative Haploidentical Transplantation: Fast Engraftment, No Evidence of Graft Rejection, and Low Incidence of Graft-Versus-Host Disease

Rocco Pastano, MD, Giovanna Andreola, MD, Federica Gigli, MD, Simona Sammassimo, MD, Mara Negri, Liptrott Jayne Sarah, Corrado Tarella, MD

Blood (2015) 126 (23): 1924.

https://doi.org/10.1182/blood.V126.23.1924.1924

Published: 2015

Journal Articles

Non-Myeloablative Haploidentical Transplantation of Unmanipulated, G-CSF Mobilized Peripheral Blood Stem Cells with High Dose Post-Transplant Cyclophosphamide: Fast Engraftment, No Evidence of Graft Rejection and Low Incidence of Graft-Versus-Host-Disease

Rocco Pastano, Giovanna Andreola, Federica Gigli, Angelo Gardellini, Mara Negri, Sarah Jayne Liptrott, Davide Radice, Giovanni Martinelli

Blood (2014) 124 (21): 3887.

https://doi.org/10.1182/blood.V124.21.3887.3887

Published: 2014

Journal Articles

Mature Circulating Endothelial Cells and Progenitors in Patients with Chronic Gvhd

Rocco Pastano, Giovanna Andreola, Patrizia Mancuso, Federica Gigli, Angelo Gardellini, Sarah Jayne Liptrott, Davide Radice, Giovanni Martinelli, MD, Francesco Bertolini

Blood (2011) 118 (21): 4700.

https://doi.org/10.1182/blood.V118.21.4700.4700

Published: 2011

Journal Articles

A New Induction Combination Therapy (ThalDoDex) for Multiple Myeloma. Preliminary Results of a Phase II Study

Simona Sammassimo, Alberto Agazzi, Simona Bassi, Liliana Calabrese, Paola Bertazzoni, Anna Vanazzi, Angelo Gardellini, Federica Gigli, Giovanna Andreola, Giovanni Martinelli, MD

Blood (2010) 116 (21): 5030.

https://doi.org/10.1182/blood.V116.21.5030.5030

Published: 2010

Journal Articles

Rituximab Plus Chlorambucil Compared with Chlorambucil and Prednisone In Patients with Untreated Follicular Lymphoma

Simona Bassi, Simona Sammassimo, Federica Gigli, Giancarlo Pruneri, Paola Bertazzoni, Jessica Quarna, Emilia Cocorocchio, Daniele Laszlo, Mara Negri, Maria Lionetti, Anna Vanazzi, Alessandra Alietti, Alberto Agazzi, Angelo Gardellini, Giovanna Andreola, Lorenzo Preda, Rocco Pastano, Giovanni Martinelli, MD

Blood (2010) 116 (21): 3956.

https://doi.org/10.1182/blood.V116.21.3956.3956

Published: 2010

Journal Articles

Rituximab Reduces Anti-UL94 and Anti-NAG-2 Antibodies Titer and Is Effective against Skin-Chronic Graft Versus Host Disease Resembling Scleroderma.

Rocco Pastano, Chiara Dell'Agnola, Caterina Bason, Federica Gigli, Cristina Rabascio, Antonio Puccetti, Gianluigi Cetto, Fedro Alessandro Peccatori, Giovanni Martinelli, Claudio Lunardi

Blood (2009) 114 (22): 4654.

https://doi.org/10.1182/blood.V114.22.4654.4654

Published: 2009

Journal Articles

Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile.

Simona Bassi, MD, Luca Nassi, MD, Giancarlo Pruneri, MD, Simona Sammassimo, MD, Paola Bertazzoni, MD, Federica Gigli, MD, Anna Vanazzi, MD, Emilia Cocorocchio, MD, Patrizia Mancuso, Cristina Rabascio, Maria Teresa Lionetti, Daniele Laszlo, MD, Giovanni Martinelli, MD

Blood (2009) 114 (22): 3754.

https://doi.org/10.1182/blood.V114.22.3754.3754

Published: 2009

Journal Articles

Rituximab and 2-Cda Activity in CLL/SLL Patients: An Update of Pharmacogenomic and Clinical Results

Paola Bertazzoni, Cristina Rabascio, Liliana Calabrese, Federica Gigli, Simona Bassi, MD, Luca Nassi, Simona Sammassimo, Sara Steffanoni, Davide Radice, Angelica Calleri, Emilia Cocorocchio, Daniele Laszlo, Giovanni Martinelli

Blood (2008) 112 (11): 3171.

https://doi.org/10.1182/blood.V112.11.3171.3171

Published: 2008

NARROW

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

SIE/Sies/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? a Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Different Epidemiology and Characteristics of Invasive Pulmonary Aspergillosis in Acute Lymphoid Leukemia in Comparison with AML: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda (REL)

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Italian Observational Study on Real-Life Use of Venetoclax in Acute Myeloid Leukemia (AVALON study): Results of Interim Analysis on Relapsed/Refractory Patients

B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions

Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features

A Cellular Therapy with Haploidentical Peripheral Hematopoietic STEM CELL Transplantation MAY be a Therapeutic Option in Patients with Relapsed Lymphoma with Chemorefractory Disease

Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study

Unmanipulated, G-CSF Mobilized Peripheral Blood Stem Cells As Graft Source for Non-Myeloablative Haploidentical Transplantation: Fast Engraftment, No Evidence of Graft Rejection, and Low Incidence of Graft-Versus-Host Disease

Non-Myeloablative Haploidentical Transplantation of Unmanipulated, G-CSF Mobilized Peripheral Blood Stem Cells with High Dose Post-Transplant Cyclophosphamide: Fast Engraftment, No Evidence of Graft Rejection and Low Incidence of Graft-Versus-Host-Disease

Mature Circulating Endothelial Cells and Progenitors in Patients with Chronic Gvhd

A New Induction Combination Therapy (ThalDoDex) for Multiple Myeloma. Preliminary Results of a Phase II Study

Rituximab Plus Chlorambucil Compared with Chlorambucil and Prednisone In Patients with Untreated Follicular Lymphoma

Rituximab Reduces Anti-UL94 and Anti-NAG-2 Antibodies Titer and Is Effective against Skin-Chronic Graft Versus Host Disease Resembling Scleroderma.

Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile.

Rituximab and 2-Cda Activity in CLL/SLL Patients: An Update of Pharmacogenomic and Clinical Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only